Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Overview
Date Founded

2000

Headquarters

780 MEMORIAL DRIVE CAMBRIDGE MA 02139

Type of Company

Public

Employees (Worldwide)

25

Industries

Biotechnology
Pharmaceuticals

Company Description

Infinity is an innovative drug discovery and development company dedicated to discovering, developing and delivering to patients best-in-class medicines for diseases with significant unmet need. We believe that our small molecule discovery and development capabilities, strategic alliances, team of highly experienced management and scientists, and corporate culture form the basis of our potential long-term competitive advantage in seeking to deliver best-in-class medicines to patients

Contact Data
Trying to get in touch with decision makers at Infinity Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chair & Chief Executive Officer

Vice President, General Counsel & Secretary

Senior Vice President & Chief Scientific Officer

Chief Medical Officer

Senior Vice President, Global Affairs

Vice President, Global Medical Affairs

Owner

Board of Directors

Chair & Chief Executive Officer at Infinity Pharmaceuticals, Inc.

Co-Founder at Karyopharm Therapeutics, Inc.

Former Partner at Venrock Associates

Founder at Paige Ai, Inc.

Chief Executive Officer & Director at Real Endpoints LLC

Former Managing Director at Bay City Capital LLC

Senior Vice President, Business Development & Pharmacogenomics at Celera Corp.

Paths to Infinity Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Infinity Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Recent Transactions
Details Hidden

Infinity Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Infinity Pharmaceuticals, Inc. issued Common Stock

Details Hidden

Infinity Pharmaceuticals, Inc. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Escrow Agent

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Underwriter

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Legal Advisor

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Managing Director

Advised onInfinity Pharmaceuticals, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Publicist

Senior Vice President at Stern Investor Relations, Inc.

Clients

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. It also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

Key Stats and Financials As of 2018
Market Capitalization
$83.7M
Total Enterprise Value
$6.79M
Earnings Per Share
$-0.2
Revenue
$22.1M
Net Profit
$-11.2M
EBITDA
$-11.7M
EBITDAMargin
-53%
Total Debt
$0
Total Equity
$52.5M
Enterprise Value Sales
0.31x
TEVNet Income
-0.6x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
-41.22%
Non-Profit Donations & Grants
Investors
Details Hidden

Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in various categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT.

Suppliers
Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, OS

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Infinity Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Infinity Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Infinity Pharmaceuticals, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/infinity-pharmaceuticals-inc-512288
  • https://relationshipscience.com/organization/infinity-pharmaceuticals-inc-512288